Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 5, 2013, Pages 374-382

  Mikami, Akiko ^a   Ohtani, Hisakazu ^b   Hori, Satoko ^a   Sawada, Yasufumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

CYP2D6; Drug interactions; Metoprolol; Paroxetine

Indexed keywords

CYTOCHROME P450 2D6; METOPROLOL; PAROXETINE;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; MATHEMATICAL MODEL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION;

ANTI-ARRHYTHMIA AGENTS; ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; METOPROLOL; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PAROXETINE;

EID: 84878062865     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201798     Document Type: Article

References (21)

1. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992; 51: 288-295. doi:10.1038/clpt.1992.24 PubMed
2. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC, Barry DZ. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992; 51: 278-287. doi:10.1038/clpt.1992.23 PubMed
3. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003; 17: 517-538. doi:10.1046/j.1472-8206.2003.00193.x PubMed
4. Hemeryck A, de Vriendt CA, Belpaire FM. Metoprolol-paroxetine interaction in human liver microsoms: stereoselective aspects abd prediction of the in vivo interaction. Drug Metab Dispos. 2001; 29: 656-663.
5. König F, Häfele M, Hauger B, Löble M, Wössner S, Wolfersdorf M. [Bradycardia after beginning therapy with metoprolol and paroxetine]. Psychiatr Prax. 1996; 23: 244-245. PubMed
6. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol. 1998; 54: 261-264. doi:10.1007/s002280050456 PubMed
7. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003; 31: 289-293. doi:10.1124/dmd.31.3.289 PubMed
8. Venkatakrishnan K, Obach RS. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos. 2005; 33: 845-852. doi:10.1124/dmd.105.004077 PubMed
9. Bloch M, Stager SV, Braun AR, Rubinow DR. Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet. 1995; 346: 57. doi:10.1016/S0140-6736(95)92691-7 PubMed
10. Tonks A. Withdrawal from paroxetine can be severe, warns FDA. BMJ. 2002; 324: 260. doi:10.1136/bmj.324.7332.260 PubMed
11. Irie H, Fujita M, Inokawa Y, Narita H. Phase I clinical study of paroxetine HCl (study 3): Pharmacokinetic profile after single oral administration of paroxetine HCl 10, 20 and 40 mg to healthy adult male volunteers. Jpn Pharmacol Ther. 2000; 28: S47-S68.
12. Murasaki M, Takahashi A, Inokawa Y, Narita H. Phase I clinical study of paroxetine HCl (study 2): Pharmacokinetic profile after single and 10-day once daily repeat oral administration of paroxetine HCl 20 mg to healthy adult male volunteers. Jpn Pharmacol Ther. 2000; 28: S37-S46.
13. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989; 80 (Suppl 350): 60-75. doi:10.1111/j.1600-0447.1989. tb07176.x PubMed
14. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10: 1093-1095. doi:10.1023/A:1018943613122 PubMed
15. Nathanson JA. Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process. J Pharmacol Exp Ther. 1988; 245: 94-101. PubMed
16. Hemeryck A, De Vriendt CA, Belpaire FM. Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction. Drug Metab Dispos. 2001; 29: 656-663. PubMed
17. Shimizu H, Nogushi H, Uno K, Takashima M, Onishi A, Ueki M. Bioavailability of slow-release metoprolol tartrate 120 mg tablet in comparison with conventional metoprolol tartrate 40 mg tablets in healthy volunteers. Yakubutsu Doutai. 1991; 6: 567-572.
18. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol. 2002; 22: 169-173. doi:10.1097/00004714-200204000-00010 PubMed
19. Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther. 1983; 34: 732-737. doi:10.1038/clpt.1983.242 PubMed
20. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002; 42: 1219-1227. doi:10.1177/009127002762491307 PubMed
21. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993; 44: 349-355. PubMed doi:10.1007/BF00316471